CN109641954A - 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 - Google Patents

抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 Download PDF

Info

Publication number
CN109641954A
CN109641954A CN201780052609.5A CN201780052609A CN109641954A CN 109641954 A CN109641954 A CN 109641954A CN 201780052609 A CN201780052609 A CN 201780052609A CN 109641954 A CN109641954 A CN 109641954A
Authority
CN
China
Prior art keywords
antibody
grem1
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780052609.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·夏洛索恩
L·C·莫顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN109641954A publication Critical patent/CN109641954A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780052609.5A 2016-08-29 2017-08-23 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 Pending CN109641954A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380562P 2016-08-29 2016-08-29
US62/380,562 2016-08-29
PCT/US2017/048137 WO2018044640A1 (en) 2016-08-29 2017-08-23 Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
CN109641954A true CN109641954A (zh) 2019-04-16

Family

ID=59791160

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780052609.5A Pending CN109641954A (zh) 2016-08-29 2017-08-23 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法

Country Status (12)

Country Link
US (1) US20180057580A1 (enExample)
EP (1) EP3504238A1 (enExample)
JP (1) JP2019529371A (enExample)
KR (1) KR20190040320A (enExample)
CN (1) CN109641954A (enExample)
AU (1) AU2017320989A1 (enExample)
CA (1) CA3031783A1 (enExample)
EA (1) EA201990613A1 (enExample)
IL (1) IL264309A (enExample)
MA (1) MA46046A (enExample)
MX (1) MX2019002382A (enExample)
WO (1) WO2018044640A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117801109A (zh) * 2024-03-01 2024-04-02 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
CN116322768A (zh) 2020-06-18 2023-06-23 里珍纳龙药品有限公司 激活素a抗体调配物和其使用方法
CA3208455A1 (en) * 2021-01-18 2022-07-21 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
CA3243581A1 (en) * 2022-04-20 2023-10-26 Kantonsspital St. Gallen ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998937A (zh) * 2011-12-12 2014-08-20 皮里斯股份公司 通过提高铁的生物利用度来预防或治疗障碍的方法及相关的药物制剂
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN105189548A (zh) * 2013-03-14 2015-12-23 瑞泽恩制药公司 Grem1的人抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998937A (zh) * 2011-12-12 2014-08-20 皮里斯股份公司 通过提高铁的生物利用度来预防或治疗障碍的方法及相关的药物制剂
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN105189548A (zh) * 2013-03-14 2015-12-23 瑞泽恩制药公司 Grem1的人抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CIUCLAN, LOREDANA等: "Treatment with Anti-Gremlin 1 Antibody Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice", 《AMERICAN JOURNAL OF PATHOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117801109A (zh) * 2024-03-01 2024-04-02 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Also Published As

Publication number Publication date
MA46046A (fr) 2019-07-03
AU2017320989A9 (en) 2019-07-11
WO2018044640A1 (en) 2018-03-08
AU2017320989A1 (en) 2019-02-07
CA3031783A1 (en) 2018-03-08
MX2019002382A (es) 2019-06-20
US20180057580A1 (en) 2018-03-01
EA201990613A1 (ru) 2019-07-31
IL264309A (en) 2019-02-28
JP2019529371A (ja) 2019-10-17
KR20190040320A (ko) 2019-04-17
EP3504238A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
CN104411719B (zh) 针对fel d1的人源抗体及其使用方法
CN109641954A (zh) 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CN109563159A (zh) 抗c5抗体及其用途
KR102146692B1 (ko) 항-ｐｄｇｆｒ-베타 항체 및 이의 용도
CN104540852B (zh) 具有pH-依赖性结合特性的抗-PCSK9抗体
AU2013222203B2 (en) Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof
TW201843176A (zh) 抗-par2抗體及其用途
TW201815821A (zh) 抗茲卡病毒抗體及使用方法
CN110041429A (zh) 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途
HUE032681T2 (en) High affinity human antibodies to pcsk9
CN112805303A (zh) 抗npr1抗体及其用途
JP2024535768A (ja) 抗ｐｖｒｉｇ／ｔｉｇｉｔ二重特異性抗体を含む医薬組成物
JP2024503784A (ja) Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質
US20250277021A1 (en) Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists
US20240425574A1 (en) Anti-pdgf-b antibodies and pharmaceutical composition thereof
TW202030202A (zh) 抗bmp10抗體及以該抗體為有效成份之針對高血壓及高血壓性疾病之治療劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190416